SCHEMBL10100529

SCHEMBL10100529

CC(=O)Nc1cccc(-c2cnc(N)c(-c3nnnn3-c3ccc(OCCCN(C)C)c(F)c3F)c2)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FYN P06241 4/20 0.46
USP7 Q93009 2/20 0.46
CHEK2 O96017 2/20 0.44
KDR P35968 6/20 0.39
FGFR3 P22607 1/20 0.37
KIT P10721 2/20 0.37
FLT3 P36888 1/20 0.37
PRKD3 O94806 1/20 0.37
PRKD1 Q15139 1/20 0.37
PRKD2 Q9BZL6 1/20 0.37
MET P08581 1/20 0.36
AKT1 P31749 1/20 0.35
PIK3C3 Q8NEB9 1/20 0.35
CHEK1 O14757 1/20 0.35
FGFR1 P11362 1/20 0.35
NEK2 P51955 1/20 0.35
MAPK15 Q8TD08 1/20 0.35
PTGIR P43119 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10100480 0.91 FYN (0.46) FYNUSP7CHEK2KITAKT1
SCHEMBL10100737 0.89 PIK3C3 (0.44) CHEK2PIK3C3
SCHEMBL10100542 0.86 FYN (0.44) FYNUSP7CHEK2KDR
SCHEMBL10100551 0.86 FYN (0.43) FYNCHEK2PRKD3PRKD1PRKD2
SCHEMBL10100545 0.86 FYN (0.55) FYNCHEK2PRKD3PRKD1PRKD2
SCHEMBL10100533 0.85 FYN (0.43) FYNCHEK2CHEK1
SCHEMBL28805610 0.83 FYN (0.52) FYNUSP7CHEK2KITPIK3C3
SCHEMBL986668 0.82 FYN (0.55) FYNUSP7CHEK2PIK3C3CHEK1
SCHEMBL10100526 0.81 FYN (0.39) FYNCHEK2
SCHEMBL988570 0.81 FYN (0.52) FYNUSP7CHEK2KITPIK3C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8518938-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-08-27 US disclosed
US-8518938-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-08-27 US disclosed
US-20120165333-A1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-28 US disclosed
US-20120165333-A1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-28 US disclosed
WO-2010048131-A1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165333-A1 C-MET PROTEIN KINASE INHIBITORS MET, PRKCH, ABL1 FYN 532/4885USP7 2668/4885CHEK2 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.